Details of the Drug Reposition

General Information of This Drug (ID: DMA6LR3)

Drug Name
OV101   DMA6LR3
Synonyms Gaboxadol

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Angelman syndrome DIS4QVXO LD90.0 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Fragile X syndrome DISE8W3A LD55 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03882918) An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT03697161) A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome. U.S.National Institutes of Health.